Skip to main content
Top
Published in: Clinical Rheumatology 4/2015

01-04-2015 | Original Article

HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients

Authors: Jing Zou, Qiang Guo, Jiachang Chi, Huawei Wu, Chunde Bao

Published in: Clinical Rheumatology | Issue 4/2015

Login to get access

Abstract

The aim of this study is to evaluate the factors associated to 1-year mortality in clinically amyopathic dermatomyositis (CADM) patients with acute interstitial lung disease (ILD). A single center of 37 cases of Chinese patients with CADM was reviewed retrospectively in Renji hospital. All CADM patients were diagnosed with ILD; there were 24 cases of acute interstitial pneumonia (AIP) and 13 cases of acute exacerbation of non-acute interstitial pneumonia non-AIP. The clinical features, including blood tests, chest high-resolution computed tomography (HRCT) score, and lung function, were analyzed, respectively. Neutrophil lymphocyte ratio (NLR), serum ferritin level, serum lactate dehydrogenase (LDH) level, and HRCT score were statistically significant factors on univariate analysis. Multivariate analysis revealed that the overall HRCT score (HR 1.134, 95 % confidence interval 1.009–1.275, P = 0.017) and serum ferritin level (HR 1.001, 95 % confidence interval 1.002–1.007, P = 0.010) were independently significant factors of 1-year mortality. C statistic value of HRCT score (c statistic value 0.867, P < 0.0001) and serum ferritin level (c statistic value 0.808, P = 0.002) were statistically significant in the classification of non-survivors. Patients with calcineurin inhibitor presented a better outcome than those without calcineurin inhibitor (log-rank test, P = 0.006). HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute ILD in CADM patients. Calcineurin inhibitor might improve the outcome of CADM patients with acute ILD.
Literature
1.
go back to reference Fathi M, Lundberg IE (2005) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 17:701–706CrossRefPubMed Fathi M, Lundberg IE (2005) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 17:701–706CrossRefPubMed
2.
go back to reference Ye S, Chen XX, Lu XY et al (2007) Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 26:1647–1654CrossRefPubMed Ye S, Chen XX, Lu XY et al (2007) Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 26:1647–1654CrossRefPubMed
3.
go back to reference Sato S, Hirakata M, Kuwana M et al (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52:1571–1576CrossRefPubMed Sato S, Hirakata M, Kuwana M et al (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52:1571–1576CrossRefPubMed
4.
go back to reference Mukae H, Ishimoto H, Sakamoto N et al (2009) Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136:1341–1347CrossRefPubMed Mukae H, Ishimoto H, Sakamoto N et al (2009) Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136:1341–1347CrossRefPubMed
5.
go back to reference Fathi M, Lundberg IE, Tornling G (2007) Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med 28:451–458CrossRefPubMed Fathi M, Lundberg IE, Tornling G (2007) Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med 28:451–458CrossRefPubMed
6.
go back to reference Sontheimer RD (2010) Clinically amyopathic dermatomyositis: what can we now tell our patients? Arch Dermatol 146:76–80PubMed Sontheimer RD (2010) Clinically amyopathic dermatomyositis: what can we now tell our patients? Arch Dermatol 146:76–80PubMed
7.
go back to reference Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine’ myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46:626–636CrossRefPubMed Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine’ myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46:626–636CrossRefPubMed
8.
go back to reference Akira M, Hamada H, Sakatani M et al (1997) CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 168:79–83CrossRefPubMed Akira M, Hamada H, Sakatani M et al (1997) CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 168:79–83CrossRefPubMed
9.
go back to reference Bernard GR, Artigas A, Brigham KL et al (1994) The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818–824CrossRefPubMed Bernard GR, Artigas A, Brigham KL et al (1994) The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818–824CrossRefPubMed
10.
go back to reference Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T et al (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 60:2193–2200CrossRefPubMed Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T et al (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 60:2193–2200CrossRefPubMed
11.
go back to reference Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J (2008) Fleischner Society: glossary terms for thoracic imaging. Radiology 246:697–722CrossRefPubMed Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J (2008) Fleischner Society: glossary terms for thoracic imaging. Radiology 246:697–722CrossRefPubMed
12.
go back to reference Ichikado K, Suga M, Müller NL et al (2002) Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and non-survivors. Am J Respir Crit Care Med 165:1551–1556CrossRefPubMed Ichikado K, Suga M, Müller NL et al (2002) Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and non-survivors. Am J Respir Crit Care Med 165:1551–1556CrossRefPubMed
13.
go back to reference Ichikado K, Suga M, Muranaka H et al (2006) Prediction of prognosis for acute respiratory distress syndrome with thinsection CT: validation in 44 cases. Radiology 238:321–329CrossRefPubMed Ichikado K, Suga M, Muranaka H et al (2006) Prediction of prognosis for acute respiratory distress syndrome with thinsection CT: validation in 44 cases. Radiology 238:321–329CrossRefPubMed
14.
go back to reference Akobeng AK (2007) Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr 96:644–647CrossRefPubMed Akobeng AK (2007) Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr 96:644–647CrossRefPubMed
15.
go back to reference Douglas WW, Tazelaar HD, Hartman TE et al (2001) Polymyositis- dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164:1182–1185CrossRefPubMed Douglas WW, Tazelaar HD, Hartman TE et al (2001) Polymyositis- dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164:1182–1185CrossRefPubMed
16.
go back to reference Marie I, Hachulla E, Cherin P et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47:614–622CrossRefPubMed Marie I, Hachulla E, Cherin P et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47:614–622CrossRefPubMed
17.
go back to reference Lakhanpal S, Lie JT, Conn DL, Martin WJ 2nd (1987) Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis 46:23–29CrossRefPubMedCentralPubMed Lakhanpal S, Lie JT, Conn DL, Martin WJ 2nd (1987) Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases. Ann Rheum Dis 46:23–29CrossRefPubMedCentralPubMed
18.
go back to reference Lee CS, Chen TL, Tzen CY, Lin FJ, Peng MJ, Wu CL, Chen PJ (2002) Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol 21:391–396CrossRefPubMed Lee CS, Chen TL, Tzen CY, Lin FJ, Peng MJ, Wu CL, Chen PJ (2002) Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol 21:391–396CrossRefPubMed
19.
go back to reference Won Huh J, Soon Kim D, Keun Lee C, Yoo B, Bum Seo J, Kitaichi M, Colby TV (2007) Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 101:1761–1769CrossRefPubMed Won Huh J, Soon Kim D, Keun Lee C, Yoo B, Bum Seo J, Kitaichi M, Colby TV (2007) Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 101:1761–1769CrossRefPubMed
20.
go back to reference Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T, Hashimoto D, Sato J, Toyoshima M, Hashizume H, Chida K (2006) Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J 28:1005–1012CrossRefPubMed Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T, Hashimoto D, Sato J, Toyoshima M, Hashizume H, Chida K (2006) Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J 28:1005–1012CrossRefPubMed
21.
go back to reference Ichikado K, Johkoh T, Ikezoe J et al (1997) Acute interstitial pneumonia: high-resolution CT findings correlated with pathology. AJR Am J Roentgenol 168:333–338CrossRefPubMed Ichikado K, Johkoh T, Ikezoe J et al (1997) Acute interstitial pneumonia: high-resolution CT findings correlated with pathology. AJR Am J Roentgenol 168:333–338CrossRefPubMed
22.
go back to reference Ichikado K, Suga M, Gushima Y et al (2000) Hyperoxiainduced diffuse alveolar damage in pigs: correlation between thin-section CT and histopathologic findings. Radiology 216:531–538CrossRefPubMed Ichikado K, Suga M, Gushima Y et al (2000) Hyperoxiainduced diffuse alveolar damage in pigs: correlation between thin-section CT and histopathologic findings. Radiology 216:531–538CrossRefPubMed
23.
go back to reference Tanizawa K, Handa T, Nakashima R et al (2013) The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med 107:745–752CrossRefPubMed Tanizawa K, Handa T, Nakashima R et al (2013) The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med 107:745–752CrossRefPubMed
24.
go back to reference Gono T, Kawaguchi Y, Hara M et al (2010) Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology 49:1354–1360CrossRefPubMed Gono T, Kawaguchi Y, Hara M et al (2010) Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology 49:1354–1360CrossRefPubMed
25.
go back to reference Kotani T, Makino S, Takeuchi T et al (2008) Early intervention with corticosteroids and cyclosporin A and 2-h postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 35:254–259PubMed Kotani T, Makino S, Takeuchi T et al (2008) Early intervention with corticosteroids and cyclosporin A and 2-h postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 35:254–259PubMed
26.
go back to reference Kotani T, Takeuchi T, Makino S et al (2011) Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol 30:1021–1028CrossRefPubMed Kotani T, Takeuchi T, Makino S et al (2011) Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol 30:1021–1028CrossRefPubMed
27.
go back to reference Ando M, Miyazaki E, Yamasue M et al (2010) Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol 29:443–445CrossRefPubMed Ando M, Miyazaki E, Yamasue M et al (2010) Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol 29:443–445CrossRefPubMed
Metadata
Title
HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients
Authors
Jing Zou
Qiang Guo
Jiachang Chi
Huawei Wu
Chunde Bao
Publication date
01-04-2015
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 4/2015
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-015-2866-5

Other articles of this Issue 4/2015

Clinical Rheumatology 4/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.